PARICCA: Phase II Study of Perindopril and Regorafenib in mCRC

• Sponsor: British Columbia Cancer Agency (Other)
• Overall Status: Completed
• CT.gov ID: NCT02651415
• Collaborator: Bayer (Industry)
• Enrollment: 12
• Location: 1
• Arm: 1
• Actual Duration (Months): 27.2
• Patients Per Site Per Month: 0.4

Study Details

Study Description

Brief Summary

The purpose of this study is to find out what effects the combination of regorafenib and perindopril has on hand-foot skin reaction (HFSR), on high blood pressure (hypertension) and on any other types of side-effects and compare it to the published incidence of the side-effects with regorafenib alone.

This research is being done in an attempt to reduce the side-effects associated with regorafenib.

Condition or Disease	Intervention/Treatment	Phase
Metastatic Colorectal Cancer	Drug: Regorafenib; Drug: Perindopril	Phase 2

Detailed Description

The investigators hypothesize that treatment of regorafenib-treated mCRC patients with perindopril may reduce HFSR compared to reported incidence and severity.

The investigators also hypothesize that treatment of regorafenib-treated mCRC patients with perindopril will likely reduce hypertension, a known adverse effect of vascular endothelial growth factor/receptor (VEGF/VEGFR) inhibition.

According to the 2014 Canadian Cancer Statistics, colorectal cancer is the second most frequently diagnosed cancer in Canadian males and the third most frequently diagnosed cancer in Canadian females, accounting for 13.9% and 11.6% of new diagnoses, respectively. Although mortality rates are declining very slightly, colorectal cancer is the second most frequent cause of cancer deaths in males and the third most frequent cause of cancer death in females, at 12.8% and 11.5% respectively.

Metastatic colorectal cancers are generally not curable. Median overall survival for patients with unresectable mCRC who receive best supportive care (BSC) is five to six months. Palliative treatment with systemic chemotherapy is the best option prolonging survival and maintaining quality of life. Patients who are exposed to all active drugs can sometimes extend survival past two years.

For many years 5 Fluorouracil (FU) was the only treatment, but the approval of irinotecan, oxaliplatin, fluoropyrimidines, as well as various monoclonal antibodies targeting VEGF and epidermal growth factor receptor (EGFR) growth factors led to the development of a number of different regimens. The ideal combination and sequence of the different agents is still not determined.

Recently, Regorafenib has shown efficacy in patients pretreated with all these options in a large phase III trial, where it prolonged overall survival (OS) compared with placebo (Grothey, et al 2013). In addition, the results were confirmed in a smaller randomised trial in the Asian population, with patients being less intensively pre-treated (Li et al, 2014). Therefore, regorafenib is now considered a standard option in pre-treated patients.

The intended outcome of successfully and significantly mitigating regorafenib-induced HFSR is that patients will be able to stay on the regorafenib for a longer period to increase efficacy. The hypothesis underlying this trial is that the co-administration of perindopril with regorafenib will mitigate HFSR symptoms.

This may not be the case, and if the HFSR is more severe with the addition of perindopril than with regorafenib alone, the study will be discontinued.

As a secondary endpoint, hypertension will also be followed.

Study Design

• Study Type: Interventional
• Actual Enrollment: 12 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Trial of the Effect of Perindopril on HFSR Incidence and Severity in Patients Receiving Regorafenib With Refractory Metastatic Colorectal Carcinoma (mCRC)
• Actual Study Start Date: Aug 1, 2016
• Actual Primary Completion Date: Mar 1, 2018
• Actual Study Completion Date: Nov 7, 2018

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Regorafenib and Perindopril Phase II, open label, single arm trial of patient with refractory mCRC treated with regorafenib (10 mg/day) and perindopril (4 mg/day). There will be no stratification in this study.

Drug: Regorafenib; Stivarga® will be used as per the marketed indication ("on label"), Coversyl will be used off-label and as such a Clinical Trial Application will be filed with Health Canada. Regorafenib will be administered 160 mg daily for 21 days of a 28 day cycle. Regorafenib will be administered with low fat breakfast, one hour after perindopril. A low fat breakfast as defined by the Stivarga ® (regorafenib) Product Monograph is one that is <30% fat, ~300-550 calories.; Other Names: Stivarga (regorafenib) or "regorafenib" ; Drug: Perindopril; COVERSYL® (perindopril erbumine) 4 mg will be administered daily for 21 days of a 28 day cycle. Perindopril will be administered orally, first thing in the morning on an empty stomach.; Other Names: COVERSYL (perindopril erbumine) or "perindopril"

Outcome Measures

Primary Outcome Measures

1. Number of Participants That Have Any Grade HFSR Toxicity [Up to Safety Follow-Up Visit (30 days +/- 7 days after permanently stopping study treatment)]

   The trial will measure the toxicities of HFSR in participants receiving both perindopril and regorafenib using the CTCAE v4.03 criteria. The toxicity of HFSR will be expressed based on the number of participants in the study (N=10) who are experiencing HFSR of all grades.

Secondary Outcome Measures

1. The Number of Participants That Experienced Any Grade of Hypertension as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril [Weekly for the first six weeks while on the study drug, then every second week and during the 30-day follow-up period]

   All grades of hypertension will be evaluated using CTCAE v4.03, weekly for the first six weeks while they are on the study drug, then every second week and during the 30-day follow-up period (Post therapy).

2. The Number of Participants That Experienced All Grade Toxicities as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril [At baseline and at D1 of each cycle while on the study drug and during the 30-day follow-up period]

   All grades of adverse events (including HFSR) will be evaluated using CTCAE v4.03, at baseline and at D1 of each cycle while they are on the study drug and during the 30-day follow-up period (Post therapy).

3. Number of Participants With Maximal Severity of HFSR as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril [Up to Safety Follow-Up Visit (30 days +/- 7 days after permanently stopping study treatment)]

   The number of participants that experienced an HFSR of grade 3 or above as assessed by CTCAE v4.03 criteria when treated with a combination of regorafenib and perindopril.

4. Median Time Course to Development of Worst Grade (Grade 3) HFSR as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril [p to Safety Follow-Up Visit (30 days +/- 7 days after permanently stopping study treatment)]

   Median time course for participants to develop worst grade 3 HFSR toxicity is defined as the time (days) from start date of study drug to date of first documented grade 3 HFSR toxicity and will be calculated only for patients who had a HFSR toxicity grade 3.

5. Median Time to Progression Free Survival (PFS) [From start date of study drugs to the date of first documented disease progression or death due to any cause.]

   Median time (in months) to PFS. PFS is defined as the time from start date of study drugs to the date of first documented disease progression (radiological or clinical) or death due to any cause, if death occurs before progression is documented. PFS will be evaluated based on RECIST v1.1 criteria, 20% progression or any new lesion.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

Patients with metastatic colorectal cancer (mCRC) who have progressed on/after, or are intolerant to all approved drugs for CRC and are eligible for regorafenib.

In order to be eligible, all inclusion criteria must be met.

A patient must:

• Understand, be willing to give consent, and sign a written informed consent form (ICF) prior to undergoing any study-specific procedure

• Be male or female and ≥ 18 years of age

• Histological or cytological documentation of adenocarcinoma of the colon or rectum.

• Patients with metastatic colorectal cancer (Stage IV) previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy.

• Progression during or within 3 months following the last administration of approved standard therapies, or have experienced intolerance to previous therapy.

• Metastatic CRC patients with measurable or non-measurable disease

• Life expectancy of at least 3 months

• Have an Eastern Cooperative Oncology Group performance status of 0 or 1 (within 14 days prior to the initiation of study treatment)

• Have adequate bone marrow, liver function, and renal function as measured by the following laboratory assessments conducted within 7 days prior to the initiation of study treatment:

• Total bilirubin < 1.5 times the upper limit of normal (ULN)

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 times the ULN (< 5 times ULN for patients with liver involvement of their cancer)

• Lipase < 1.5 times the ULN

• Serum creatinine < 1.5 times the ULN

• Glomerular filtration rate > 30 mL/min/1.73 m2 according to the modified diet in renal disease abbreviated formula

• International normalized ratio (INR) of prothrombin time (PT; PT-INR) and partial thromboplastin time (PTT) < 1.5 times the ULN

• Platelet count > 100000 /mm3, hemoglobin > 9 g/dL, absolute neutrophil count > 1500/mm3.

• Alkaline phosphatase limit ≤ 2.5 times the ULN (< 5 times ULN for patients with liver involvement of their cancer)

• If female and of childbearing potential, have a NEGATIVE result on a pregnancy test performed a maximum of 7 days before initiation of study treatment.

• If female and of childbearing potential or if male, must agree to use adequate contraception (e.g., abstinence, intrauterine device, oral contraceptive, or double-barrier method) based on the judgment of the investigator or a designated associate from the date on which the ICF is signed until 6 months after the last dose of study drug.

Exclusion Criteria:

Patients who meet the following criteria at the time of screening will be excluded:

• Patients with hypotension (less than 90/60mm Hg) or at risk of symptomatic hypotension (fainting or dizziness) will be excluded.

• Prior treatment with regorafenib or any VEGFR-targeting kinase inhibitor.

• Previous assignment to treatment during this study. Patients permanently withdrawn from study participation will not be allowed to re-enter the study.

• Concurrent cancer requiring treatment that is distinct in primary site or histology from colorectal cancer.

• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication.

• Unstable/uncontrolled cardiac disease including: congestive heart failure > New York Heart Association (NYHA) class 2; unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months); myocardial infarction less than 6 months before start of study drug; cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted).

• Uncontrolled hypertension. (Systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management).

• Patients with phaeochromocytoma.

• Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months before start of study medication.

• Ongoing infection > grade 2 NCI-CTCAE version 4.03

• Known history of human immunodeficiency virus (HIV) infection.

• Known history of chronic hepatitis B or C.

• Patients with seizure disorder requiring medication.

• Symptomatic metastatic brain or meningeal tumors unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Also the patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for one month prior to and following screening radiographic studies)

• History of organ allograft

• Patients with evidence or history of bleeding diasthesis, including patients who have had a transfusion and/or radiographic endoscopic or elective operative interaction to control the bleeding or hemorrhage event within four weeks prior to the study

• Non-healing wound, ulcer, or bone fracture.

• Renal impairment or failure requiring hemo-or peritoneal dialysis.

• Patients with severe hepatic impairment.

• Dehydration NCI-CTC version 4.03 grade > 1.

• Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results

• Any illness or medical conditions that are unstable or could jeopardize the safety of the study

• Interstitial lung disease with ongoing signs and symptoms at the time of informed consent.

• Persistent proteinuria of Common Terminology Criteria (CTC) Grade 3 or higher. Quantification of proteinuria done by urinary protein/creatinine ratio on a random urine sample preferably taken at mid-morning. If protein/creatinine ratio is greater than 30g/mol Creat, then a 24-hour urine protein test should be performed to confirmed Grade 3 or higher proteinuria (> 3.5 g/24 hours).

• Patients unable to swallow oral medications

• Any malabsorption condition

• Unresolved toxicity higher than NCI-CTCAE (version 4.03) Grade 1 attributed to any prior therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity ≤Grade 2

• Patients who are hypersensitive to perindopril, as well as those hypersensitive to regorafenib, sorafenib, drugs in the same class or any ingredient in the formulation.

• Patients who cannot tolerate the full dose of perindopril (4 mg) for any reason.

• Patients receiving systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, hormonal therapy and experimental or approved therapies during this trial or within 14 days before starting to receive study medication.

In addition, patients will be excluded for the following reasons (From perindopril monograph).

• Patients with a history of hereditary/idiopathic angioedema, or angioedema related to previous treatment with an angiotensin converting enzyme inhibitor.

• Pregnant women or those planning to become pregnant, nursing women.

• Patients with hereditary problems of galactose intolerance, glucose-galactose malabsorption, or the Lapp lactase deficiency.

• Patients with pre-existing anti-hypertension treatment with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) are to be excluded. Co-administration of ACE inhibitors, including COVERSYL®, with other agents blocking the Renin-Angiotensin System (RAS), such as ARBs or aliskiren-containing drugs, will not be allowed, since such treatment has been associated with an increased incidence of severe hypotension, renal failure, and hyperkalemia.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	BC Cancer Agency - Vancouver Cancer Centre	Vancouver	British Columbia	Canada	V5Z 4E6

Sponsors and Collaborators

• British Columbia Cancer Agency
• Bayer

Investigators

• Principal Investigator: Daniel J Renouf, MD, British Columbia Cancer Agency

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Feb 8, 2017

More Information

Publications

• Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol. 2000 Jan;35(1):60-6.
• Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G, Kluft C, Blann A, Cokkinos D, Ferrari R; EUROPA Investigators; PERTINENT Investigators and the Statistical Committee. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007 Jan 1;73(1):237-46. Epub 2006 Nov 10.
• Ceconi C, Francolini G, Olivares A, Comini L, Bachetti T, Ferrari R. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. 2007 Dec 22;577(1-3):1-6. Epub 2007 Aug 3.
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
• Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004 Feb;18(2):338-40. Epub 2003 Dec 4.
• Grothey A, George S, van Cutsem E, Blay JY, Sobrero A, Demetri GD. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist. 2014 Jun;19(6):669-80. doi: 10.1634/theoncologist.2013-0059. Epub 2014 May 12.
• Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22.
• Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J, Kim TW; CONCUR Investigators. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015 Jun;16(6):619-29. doi: 10.1016/S1470-2045(15)70156-7. Epub 2015 May 13.
• Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014 Oct;71(4):787-94. doi: 10.1016/j.jaad.2014.03.019. Epub 2014 May 1. Review.
• Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005 Jul;6(7):491-500. Review.
• Taddei S: New evidence for entothelial protection. Medicographia, a Servier publication Vol 34:17-23, 2012
• Zhuo JL, Mendelsohn FA, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension. 2002 Feb;39(2 Pt 2):634-8.

• Responsible Party: British Columbia Cancer Agency
• ClinicalTrials.gov Identifier: NCT02651415
• Other Study ID Numbers: H15-02424
• First Posted: Jan 11, 2016
• Last Update Posted: Sep 12, 2019
• Last Verified: Sep 1, 2019

• Keywords provided by British Columbia Cancer Agency: Metastatic colorectal cancer; Metastatic colorectal carcinoma; mCRC; Regorafenib; Stivarga; Perindopril; Perindopril erbumine; Coversyl
• Additional relevant MeSH terms: Colorectal Neoplasms; Perindopril

Study Results

Participant Flow

Recruitment Details	Study conducted from August 2016 - November 2018. 12 Patients were enrolled but only 10 were evaluable.

Arm/Group Title	Single Arm Trial
Arm/Group Description	All patients in this single-arm trial will receive treatment with regorafenib and perindopril.
Period Title: Overall Study
STARTED	12
COMPLETED	10
NOT COMPLETED	2

Baseline Characteristics

Arm/Group Title	Regorafenib and Perindopril
Arm/Group Description	Phase II, open label, single arm trial of patient with refractory metastatic colorectal carcinoma (mCRC) treated with regorafenib (10 mg/day) and perindopril (4 mg/day). There will be no stratification in this study. Regorafenib: Stivarga® will be used as per the marketed indication ("on label"), Coversyl will be used off-label and as such a Clinical Trial Application will be filed with Health Canada. Regorafenib will be administered 160 mg daily for 21 days of a 28 day cycle. Regorafenib will be administered with low fat breakfast, one hour after perindopril. A low fat breakfast as defined by the Stivarga ® (regorafenib) Product Monograph is one that is <30% fat, ~300-550 calories. Perindopril: COVERSYL® (perindopril erbumine) 4 mg will be administered daily for 21 days of a 28 day cycle. Perindopril will be administered orally, first thing in the morning on an empty stomach.
Overall Participants	12
Age (Count of Participants)
<=18 years	0 0%
Between 18 and 65 years	6 50%
>=65 years	4 33.3%
Age (Years) [Median (Full Range) ]
Median (Full Range) [Years]	60.65
Sex: Female, Male (Count of Participants)
Female	5 41.7%
Male	5 41.7%
Race/Ethnicity, Customized (participants) [Number]
Asian	5 41.7%
Black	1 8.3%
Caucasian	4 33.3%
Region of Enrollment (participants) [Number]
Canada	10 83.3%

Outcome Measures

1. Primary Outcome

Title	Number of Participants That Have Any Grade HFSR Toxicity
Description	The trial will measure the toxicities of HFSR in participants receiving both perindopril and regorafenib using the CTCAE v4.03 criteria. The toxicity of HFSR will be expressed based on the number of participants in the study (N=10) who are experiencing HFSR of all grades.
Time Frame	Up to Safety Follow-Up Visit (30 days +/- 7 days after permanently stopping study treatment)

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Single Arm Trial
Arm/Group Description	All patients in this single-arm trial will receive treatment with regorafenib and perindopril.
Measure Participants	10
Count of Participants [Participants]	7 58.3%

2. Secondary Outcome

Title	The Number of Participants That Experienced Any Grade of Hypertension as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril
Description	All grades of hypertension will be evaluated using CTCAE v4.03, weekly for the first six weeks while they are on the study drug, then every second week and during the 30-day follow-up period (Post therapy).
Time Frame	Weekly for the first six weeks while on the study drug, then every second week and during the 30-day follow-up period

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Single Arm Trial
Arm/Group Description	All patients in this single-arm trial will receive treatment with regorafenib and perindopril.
Measure Participants	10
Count of Participants [Participants]	6 50%

3. Secondary Outcome

Title	The Number of Participants That Experienced All Grade Toxicities as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril
Description	All grades of adverse events (including HFSR) will be evaluated using CTCAE v4.03, at baseline and at D1 of each cycle while they are on the study drug and during the 30-day follow-up period (Post therapy).
Time Frame	At baseline and at D1 of each cycle while on the study drug and during the 30-day follow-up period

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Single Arm Trial
Arm/Group Description	All patients in this single-arm trial will receive treatment with regorafenib and perindopril.
Measure Participants	10
Number [participants]	10 83.3%

4. Secondary Outcome

Title	Number of Participants With Maximal Severity of HFSR as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril
Description	The number of participants that experienced an HFSR of grade 3 or above as assessed by CTCAE v4.03 criteria when treated with a combination of regorafenib and perindopril.
Time Frame	Up to Safety Follow-Up Visit (30 days +/- 7 days after permanently stopping study treatment)

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Single Arm Trial
Arm/Group Description	All patients in this single-arm trial will receive treatment with regorafenib and perindopril.
Measure Participants	10
Count of Participants [Participants]	5 41.7%

5. Secondary Outcome

Title	Median Time Course to Development of Worst Grade (Grade 3) HFSR as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril
Description	Median time course for participants to develop worst grade 3 HFSR toxicity is defined as the time (days) from start date of study drug to date of first documented grade 3 HFSR toxicity and will be calculated only for patients who had a HFSR toxicity grade 3.
Time Frame	p to Safety Follow-Up Visit (30 days +/- 7 days after permanently stopping study treatment)

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Single Arm Trial
Arm/Group Description	All patients in this single-arm trial will receive treatment with regorafenib and perindopril.
Measure Participants	10
Median (Full Range) [days]	12

6. Secondary Outcome

Title	Median Time to Progression Free Survival (PFS)
Description	Median time (in months) to PFS. PFS is defined as the time from start date of study drugs to the date of first documented disease progression (radiological or clinical) or death due to any cause, if death occurs before progression is documented. PFS will be evaluated based on RECIST v1.1 criteria, 20% progression or any new lesion.
Time Frame	From start date of study drugs to the date of first documented disease progression or death due to any cause.

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Single Arm Trial
Arm/Group Description	All patients in this single-arm trial will receive treatment with regorafenib and perindopril.
Measure Participants	10
Median (95% Confidence Interval) [Months]	2.60

Adverse Events

Time Frame	The PARICCA study was conducted from August 2016 to November 2018 and during this time period, adverse event (AE) data were collected. All grades of AE (including HFSR) were evaluated using CTCAE v4.03, at baseline and at D1 of each cycle while they are on the study drug and during the 30-day follow up period (Post therapy).
Arm/Group Title	Single Arm Trial
Arm/Group Description	All patients in this single-arm trial will receive treatment with regorafenib and perindopril.
All Cause Mortality
	Single Arm Trial
	Affected / at Risk (%)	# Events
Total	10/10 (100%)
Serious Adverse Events
	Single Arm Trial
	Affected / at Risk (%)	# Events
Total	1/10 (10%)
Gastrointestinal disorders
RUQ Abdominal Pain; Pneumonia	1/10 (10%)
Malignant Neoplasm, Grade 5	1/10 (10%)
Other (Not Including Serious) Adverse Events
	Single Arm Trial
	Affected / at Risk (%)	# Events
Total	10/10 (100%)
Gastrointestinal disorders
Abdominal pain	5/10 (50%)
Mucositis oral	6/10 (60%)
Diarrhea	5/10 (50%)
Nausea	4/10 (40%)
Constipation	4/10 (40%)
Vomiting	3/10 (30%)
Ascites	3/10 (30%)
Rectal pain	2/10 (20%)
Dysphagia	2/10 (20%)
General disorders
Fatigue	7/10 (70%)
Fever	3/10 (30%)
Non-cardiac chest pain	2/10 (20%)
Localized edema	2/10 (20%)
Pain	1/10 (10%)
Chills	1/10 (10%)
Infections and infestations
Urinary tract infection	3/10 (30%)
Investigations
Increased AST	3/10 (30%)
Weight loss	1/10 (10%)
Blood bilirubin increased	2/10 (20%)
Alkaline phosphatase increased	1/10 (10%)
Lipase increased	1/10 (10%)
INR increased	1/10 (10%)
Metabolism and nutrition disorders
Anorexia	6/10 (60%)
Hypokalemia	2/10 (20%)
Musculoskeletal and connective tissue disorders
Myalgia	5/10 (50%)
Arthralgia	4/10 (40%)
Pain in extremity	3/10 (30%)
Back pain	2/10 (20%)
Generalized muscle weakness	1/10 (10%)
Cramps (leg)	1/10 (10%)
Nervous system disorders
Headache	3/10 (30%)
Paresthesia	1/10 (10%)
Psychiatric disorders
Insomnia	1/10 (10%)
Renal and urinary disorders
Hematuria	1/10 (10%)
Reproductive system and breast disorders
Pelvic pain	2/10 (20%)
Respiratory, thoracic and mediastinal disorders
Hoarseness	4/10 (40%)
Dyspnea	2/10 (20%)
Cough	2/10 (20%)
Epistaxis	1/10 (10%)
Haemoptysis	1/10 (10%)
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysesthesia syndrome	7/10 (70%)
Rash maculo-papular	4/10 (40%)
Dry skin	3/10 (30%)
Erythema multiforme	1/10 (10%)
Pruritus	1/10 (10%)
Vascular disorders
Hypertension	6/10 (60%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.